An interventional study of Omega 3 FA (Fish Oil) and Training in Cancer Cachexia, Omega 3 and Resistance Training, sponsored by University of Erlangen-Nürnberg Medical School. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by University of Erlangen-Nürnberg Medical School · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Cancer cachexia is a common and prognostically relevant complication of advanced malignancies, characterized by systemic inflammation, increased catabolism, and reduced nutritional intake, leading to a progressive loss of skeletal muscle mass, physical performance, and quality of life. Muscle wasting negatively affects the tolerability and efficacy of oncological therapies and exacerbates distressing symptoms such as fatigue. Consequently, international guidelines recommend combined nutritional and exercise interventions as key components of supportive cancer care. However, due to treatment-related limitations, conventional exercise programs are often difficult to implement, highlighting the need for feasible, time-efficient, and individually adaptable training concepts suitable for daily life.
In addition, adequate protein-rich nutrition is essential and may be supported by targeted nutritional supplementation. Omega-3 fatty acids, particularly eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have demonstrated anti-inflammatory effects and beneficial influences on nutritional status, quality of life, and potentially skeletal muscle mass.
The aim of the present project is to investigate, in a randomized, placebo-controlled trial, whether the combination of progressive resistance training (twice-weekly TheraBand-based exercise) and omega-3 supplementation (daily intake of 2 g EPA and 1 g DHA administered as fish oil capsules) can improve muscle status, physical performance, and patient-relevant outcomes such as quality of life, appetite, and fatigue in cancer patients at high risk of developing cancer cachexia.
10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's planned enrollment of 288 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →University of Erlangen-Nürnberg Medical School is the lead sponsor of 277 studies on the registry; 53 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo (corn oli) and no training program
Dietary Supplement: Corn Oil Placebo, 4 capsules/day for 12 weeks
Placebo (corn oli) and 2x weekly resistance training
Behavioral: Training · Dietary Supplement: Corn Oil Placebo, 4 capsules/day for 12 weeks
Verum (Omega-3-capsules with fish oil) and no training program
Dietary Supplement: Omega 3 FA (Fish Oil)
Verum (Omega-3-capsules with fish oil) and 2x weekly resistance training
Dietary Supplement: Omega 3 FA (Fish Oil) · Behavioral: Training
4x capsules containing 500 mg EPA and 250 mg DHA
2x weekly resistance training
4x capsueles daily
Skeletal Muscle Status I
Body composition: BIA (SMM in kg)
Time frame: Baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Skeletal Muscle Status II
Muscle function: Tensiomyography (TMG) (Dm in mm, Tc in ms, Td in ms, Ts in ms, Tr in ms)
Time frame: Baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Skeletal Muscle Status III
Maximal muscle strength: estimated one-repetition maximum (1-RM in kg)
Time frame: Baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Skeletal Muscle Status IV
Handgrip strength: dynamometer (in kg)
Time frame: Baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Physical Performance I
Functional exercise capacity: 6-minute walk test (distance in m)
Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Physical Performance II
Daily physical activity: International Physical Activity Questionnaire (IPAQ)
Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Physical Performance III
Accelerometry over 7 consecutive days (steps)
Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Nutritional Status I
Malnutrition screening: Nutritional Risk Screening Score (NRS 2002) \[0 (no risk) - 7 (highest risk)\]
Time frame: baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, 6 months follow-up after study completion
Nutritional Status II
Dietary intake and nutrient analysis: 3 or 7-day dietary record for assessment of energy and protein intake (in g)
Time frame: baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, 6 months follow-up after study completion
Nutritional Status III
Dietary intake and nutrient analysis: 3 or 7-day dietary record and assessment of consumption of EPA- and DHA-rich foods, and omega-3/omega-6 fatty acid ratio (in g)
Time frame: baseline, 3 weeks, 6 weeks, 9 weeks, 12 weeks, 6 months follow-up after study completion
Patient-Reported Outcomes I
Appetite perception: VAS-scale (Visual Analog Scale 0 \[none\] - 10 \[excessive\])
Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Patient-Reported Outcomes II
Quality of life: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30)
Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Patient-Reported Outcomes III
Fatigue: The Functional Assessment of Chronic Illness Therapy (FACIT) - Scale \[0-52, higher scores indicate better quality of life and less severe fatigue\]
Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Patient-Reported Outcomes III
Symptom burden and treatment-related side effects: Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Patient-Reported Outcomes IV
Edmonton Symptom Assessment Scale (ESAS) \[0 (none) - 10 (worst possible)\]
Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Omega-3-Index
Laboratory Endpoints: Omega-3 Fatty Acid Status as Blood-Based Biomarkers
Time frame: baseline, 6 weeks, 12 weeks, 6 months follow-up after study completion
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Oct 2028, 33 months after the start.
Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 33 months is above that.
Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fish Oils
University of Erlangen-Nürnberg Medical School →